Note: This document contains side effect information about aflibercept ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Eylea.
More frequent side effects include: increased intraocular pressure. See below for a comprehensive list of adverse effects.
Applies to aflibercept ophthalmic: intraocular solution
Along with its needed effects, aflibercept ophthalmic (the active ingredient contained in Eylea) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking aflibercept ophthalmic:
Incidence not known
Some side effects of aflibercept ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to aflibercept ophthalmic: intravitreal solution
The more commonly reported adverse reactions have included conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.
Very common (10% or more): Conjunctival hemorrhage (28%), eye pain (13%),
Common (1% to 10%): Cataract, vitreous floaters, corneal erosion, intraocular pressure increased, conjunctival hyperemia, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increased, vision blurred, intraocular inflammation, retinal pigment epithelium tear, injection site hemorrhage, eyelid edema, corneal edema, retinal degeneration, cataract, cataract nuclear, cataract subcapsular, corneal abrasion, intraocular pressure increased, vitreous floaters
Uncommon (0.1% to 1%): Retinal detachment, retinal tear, endophthalmitis injection site pain, traumatic cataract
Common (1% to 10%): Injection site pain
Intravitreal use of VEGF inhibitors has been associated with a potential risk of arterial thromboembolic events (ATEs) defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including death of unknown cause). In wet age-related macular degeneration (AMD) studies, 1.8% (n=32/1824) and 1.5% (n=9/595) of patients treated with this drug or ranibizumab, respectively, experienced an ATE in the first 52 weeks and 3.3% and 3.2% through 96 weeks, respectively. In the diabetic macular edema (DME) studies, ATEs were reported at incidences of 3.3% (n=19/578) and 2.8% (n=8/287) through week 52, and 6.4% (n=37/578) and 4.2% (n=12/287) through week 100, in patients receiving 2 different dosing regimens of this drug or macular laser photocoagulation (after the first 24 weeks, all patients could receive drug or laser treatment). No ATEs have been reported in the first 6 months of the retinal vein occlusion (RVO) studies.
Common (1% to 10%): Arterial thromboembolic events
Uncommon (0.1% to 1%): Hypersensitivity
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Eylea